Spero Therapeutics (SPRO)
Develops SP001 while retaining economics linked to GSK-marketed Utebzi.
$1.22
At close+0.02 (+1.67%)
Something off on this page? Send us feedback.
Next report
Nov 12, 2026
in 70 days
EPS estimate
−$0.16
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.38−$0.25−$0.03−$0.13$0.53−$0.13−$0.16Pending
Estimate−$0.35−$0.55−$0.38−$0.25−$0.20−$0.18−$0.17−$0.16
Surprise−8.6%+54.5%+92.1%+48.0%+365.0%+27.8%+5.9%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$9.4M$5.9M$11.8M$3.0M$41.3M$258.0K$0Pending
Estimate$6.2M$11.0M$11.0M$12.0M$26.0M$258.0K——
Surprise+50.9%−46.6%+7.3%−74.6%+58.8%0.0%——
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.16 | — | — |
| Aug 2026 | −$0.17 | −$0.16 | +5.9% |
| May 2026 | −$0.18 | −$0.13 | +27.8% |
| Mar 2026 | −$0.20 | $0.53 | +365.0% |
| Nov 2025 | −$0.25 | −$0.13 | +48.0% |
The latest year is open to everyone — the 36 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Apr 2018 | |||
| Dec 2017 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Dec 2016 | |||
| Sep 2016 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | −$0.16 | — | — | — | — | — | — |
| Aug 12, 2026 | −$0.17 | −$0.16 | +5.9% | — | $0 | — | +4.2% |
| May 13, 2026 | −$0.18 | −$0.13 | +27.8% | $258.0K | $258.0K | 0.0% | +13.1% |
| Mar 26, 2026 | −$0.20 | $0.53 | +365.0% | $26.0M | $41.3M | +58.8% | −1.7% |
| Nov 13, 2025 | −$0.25 | −$0.13 | +48.0% | $12.0M | $3.0M | −74.6% | −1.2% |
The latest year is open to everyone — the 36 quarters behind it read with an account. Sign in | |||||||
| Aug 12, 2025 | |||||||
| May 13, 2025 | |||||||
| Mar 27, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Aug 5, 2024 | |||||||
| May 15, 2024 | |||||||
| Mar 13, 2024 | |||||||
| Nov 13, 2023 | |||||||
| Aug 10, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 30, 2023 | |||||||
| Nov 14, 2022 | |||||||
| Aug 10, 2022 | |||||||
| May 16, 2022 | |||||||
| Mar 31, 2022 | |||||||
| Nov 10, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Mar 11, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 8, 2020 | |||||||
| Mar 16, 2020 | |||||||
| Nov 4, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 9, 2019 | |||||||
| Mar 14, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 9, 2018 | |||||||
| May 10, 2018 | |||||||
| Apr 2, 2018 | |||||||
| Dec 14, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Mar 31, 2017 | |||||||
| Dec 31, 2016 | |||||||
| Sep 30, 2016 | |||||||